Buy Propecia, Finpecia, Proscar (Finasteride) to treat hair loss and BPH
Cheap qualitative Finasteride medication 1 mg and 5 mg tablets online
HOW AND WHERE TO BUY FINASTERIDE (PROPECIA, FINPECIA, PROSCAR, FINCAR) 1 MG, 5 MG TABLETS OR CAPSULES ONLINE:
PROSCAR (FINASTERIDE): PHARMACOKINETICS
In a study of 15 healthy young subjects, the mean bioavailability of finasteride 5-mg tablets was 63% (range 34-108%), based on the ratio of area under the curve (AUC) relative to an intravenous (IV) reference dose. Maximum finasteride plasma concentration averaged 37 ng/mL (range, 27-49 ng/mL) and was reached 1-2 hours postdose. Bioavailability of finasteride was not affected by food.
Mean steady-state volume of distribution was 76 liters (range, 44-96 liters). Approximately 90% of circulating finasteride is bound to plasma proteins. There is a slow accumulation phase for finasteride after multiple dosing. After dosing with 5 mg/day of finasteride for 17 days, plasma concentrations of finasteride were 47 and 54% higher than after the first dose in men 45-60 years old (n=12) and >= 70 years old (n=12), respectively. Mean trough concentrations after 17 days of dosing were 6.2 ng/mL (range, 2.4-9.8
ng/mL) and 8.1 ng/mL (range, 1.8-19.7 ng/mL), respectively, in the two age groups. Although steady state was not reached in this study, mean trough plasma concentration in another study in patients with BPH (mean age, 65 years) receiving 5 mg/day was 9.4 ng/mL (range, 7.1-13.3 ng/mL; n=22) after over a year of dosing.
Finasteride (Proscar) has been shown to cross the blood brain barrier but does not appear to distribute preferentially to the CSF.
In 2 studies of healthy subjects (n=69) receiving Proscar (Finasteride) 5 mg tablets per day for 6-24 weeks, finasteride concentrations in semen ranged from undetectable ( < 0.1 ng/mL) to 10.54 ng/mL. In an earlier study using a less sensitive assay, finasteride concentrations in the semen of 16 subjects receiving Proscar (Finasteride) 5 mg/day ranged from undetectable ( < 1.0 ng/mL) to 21 ng/mL. Thus, based on a 5 ml ejaculate volume, the amount of finasteride in semen was estimated to be 50- to 100-fold less than the dose of finasteride (5 mcg) that had no effect on circulating DHT levels in men.
Finasteride is extensively metabolized in the liver, primarily via the cytochrome P450 3A4 enzyme subfamily. Two metabolites, the t-butyl side chain monohydroxylated and monocarboxylic acid metabolites, have been identified that possess no more than 20% of the 5-alpha-reductase inhibitory activity of Proscar (Finasteride) tablets.
In healthy young subjects (n=15), mean plasma clearance of finasteride was 165 mL/min (range, 70279 mL/min) and mean elimination half-life in plasma was 6 hours (range, 3-16 hours). Following an oral dose of 14C-finasteride in man (n=6), a mean of 39% (range, 32-46%) of the dose was excreted in the urine in the form of metabolites; 57% (range, 51-64%) was excreted in the feces.
The mean terminal half-life of finasteride in subjects >= 70 years of age was approximately 8 hours (range, 6-15 hours; n=12), compared with 6 hours (range, 4-12 hours; n=12) in subjects 45-60 years of age. As a result, mean AUC(0-24 hr) after 17 days of dosing was 15% higher in subjects >= 70 years of age than in subjects 45-60 years of age (p=0.02).
Finasteride pharmacokinetics have not been investigated in patients < 18 years of age.
Proscar is not indicated for use in pediatric patients.
Finasteride is not indicated for use in women.
No dosage adjustment is necessary in the elderly. Although the elimination rate of finasteride is decreased in the elderly, these findings are of no clinical significance.
The effect of race on finasteride pharmacokinetics has not been studied.
The effect of hepatic impairment on finasteride pharmacokinetics has not been studied. Caution should be exercised in the administration of Proscar tablets in those patients with liver function abnormalities, as finasteride is metabolized extensively in the liver.
No dosage adjustment is necessary in patients with renal impairment. In patients with chronic renal impairment, with creatinine clearances ranging from 9.0 to 55 mL/min, AUC, maximum plasma concentration, half-life, and protein binding after a single dose of 14C-finasteride were similar to values obtained in healthy volunteers. Urinary excretion of metabolites was decreased in patients with renal impairment. This decrease was associated with an increase in fecal excretion of metabolites. Plasma concentrations of metabolites were significantly higher in patients with renal impairment (based on a 60% increase in total radioactivity AUC). However, Finasteride (Proscar) has been well tolerated in BPH patients with normal renal function receiving up to 80 mg/day for 12 weeks, where exposure of these patients to metabolites would presumably be much greater.
Buy Proscar (Finasteride) Online
Proscar prescribing information
Copyright © Buy Finasteride Online